ArticleJournal of natural medicines2026
Ganoderma lucidum polysaccharide protects against myocardial ischemic injury by restoring myocardial energy metabolism and alleviating oxidative stress in mice and AC16 cardiomyocytes.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Myocardial ischemic injury is characterized by impaired energy metabolism and oxidative stress, which contribute to cardiac dysfunction and disease progression. Ganoderma lucidum polysaccharide (GLP), a major bioactive component of Ganoderma lucidum, exhibits various pharmacological activities; however, its protective effects against myocardial ischemic injury and underlying mechanisms remain unclear. This study investigated the effects of GLP against isoproterenol (ISO)-induced myocardial ischemic injury and its involvement in metabolic regulation and oxidative stress. A mouse myocardial ischemic injury model was established by subcutaneous injection of ISO (2 mg/kg/day) for 11days. Mice were randomly divided into normal control, model, GLP treatment groups with GLP administered orally at 50 and 100 mg/kg/day, and at 50 mg/kg/day by intraperitoneal injection. An ISO-induced injury model in vitro was established using AC16 cardiomyocytes, which were pretreated with GLP (0.25 ~ 1.00 µg/mL) followed by ISO exposure (40 µM, 24 h). GLP significantly alleviated ISO-induced myocardial injury, reduced cardiac hypertrophy, improved histopathological alterations, and decreased serum AST and LDH activities in mice. Similar protective effects were observed in AC16 cells. Moreover, GLP restored myocardial energy metabolic homeostasis, by improving ATP, phosphocreatine, creatine, and total adenine nucleotides levels, while reducing cAMP accumulation. GLP also alleviated oxidative stress by decreasing malondialdehyde level and enhancing total superoxide dismutase activity. Furthermore, GLP increased the expression of AMPK-α2, phosphorylated AMPK-α2, PGC-1α, and PPAR-α in myocardial tissue. These findings suggest that GLP protects against ISO-induced myocardial ischemic injury by improving myocardial energy metabolism and reducing oxidative stress, with AMPK/PGC-1α/PPAR-α-related metabolic regulation potentially contributing to its cardioprotective effects.
Indexed as
Identifiers
42830376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.